Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
MedImmune, Advaxis Test Combo Therapy
by Rick Mullin
July 28, 2014
| A version of this story appeared in
Volume 92, Issue 30
AstraZeneca’s MedImmune unit will collaborate with Advaxis, a U.S.-based specialist in developing cancer immunotherapies. The pair plans Phase I and II trials that combine MedImmune’s MEDI4736, an anti-PD-L1 immune checkpoint inhibitor, with Advaxis’s ADXS-HPV vaccine as a treatment for patients with certain cervical, head, and neck cancers associated with human papillomavirus. Advaxis will fund and conduct the study. MedImmune has first right of negotiation for further development of combinations involving MEDI4736 and ADXS-HPV.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter